Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-003864.pdf
0001558370-16-003864.rtf
0001558370-16-003864.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0000921895-16-003392.pdf
0000921895-16-003392.rtf
0000921895-16-003392.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0001144204-16-082682.pdf
0001144204-16-082682.rtf
0001144204-16-082682.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0000315066-16-004895.pdf
0000315066-16-004895.rtf
SC 13G A statement of beneficial ownership of common stock by certain persons View HTML
0001193125-16-457617.pdf
0001193125-16-457617.rtf
0001193125-16-457617.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-003101.pdf
0001558370-16-003101.rtf
0001558370-16-003101.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018639.pdf
0001179110-16-018639.rtf
0001179110-16-018639.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018642.pdf
0001179110-16-018642.rtf
0001179110-16-018642.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018641.pdf
0001179110-16-018641.rtf
0001179110-16-018641.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018643.pdf
0001179110-16-018643.rtf
0001179110-16-018643.xls